Noradrenalin Ligula Pharma (Noradrenaline Tartrate)

Noradrenaline acts as a direct agonist at α1‑adrenergic receptors, causing strong vasoconstriction that increases systemic vascular resistance, and at β1‑adrenergic receptors, enhancing heart contractility and rate. The combined effect raises arterial pressure and cardiac output, helping to restore adequate tissue perfusion during severe circulatory failure.

The specific dose of Noradrenalin Ligula Pharma is determined by the treating physician based on the patient’s clinical condition, blood pressure response, and desired therapeutic goal. It is delivered as an intravenous infusion that is titrated in real‑time to achieve target hemodynamic parameters, with dosing adjustments made by the medical team.

Safety data for noradrenaline in pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision must be made by the prescribing clinician.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain logistics if needed), and any required import documentation.

Noradrenaline is generally preferred over dopamine for most shock states because it provides potent α1‑mediated vasoconstriction with less tachyarrhythmia risk. Compared with epinephrine, it has a stronger vascular effect and a weaker β2‑mediated metabolic impact, making it suitable for sustained blood‑pressure support while minimizing excess heart‑rate acceleration.

The product must be stored at 2‑8 °C in a refrigerator, protected from light, and should never be frozen or shaken. It should be kept in its original packaging until use, and any unused portion must be discarded according to local regulations after the recommended in‑use period.

Noradrenalin Ligula Pharma is administered intravenously, typically as a continuous infusion. The infusion is started at a low rate and titrated upward based on real‑time blood‑pressure measurements and clinical response, under the supervision of trained medical personnel in an intensive‑care or emergency environment.

Serious risks include myocardial ischemia, severe arrhythmias, extreme hypertension that can lead to cerebrovascular hemorrhage, and peripheral tissue necrosis at the infusion site. Continuous hemodynamic monitoring and prompt adjustment of the infusion rate are essential to mitigate these potentially life‑threatening complications.

Patients with known pheochromocytoma, uncontrolled hypertension, or severe peripheral vascular disease should not receive noradrenaline due to the high risk of exacerbating these conditions. Additionally, individuals with hypersensitivity to noradrenaline or any excipients in the formulation should avoid its use.